The two trials you need to know about from SIR 2013
W. L. Gore's Flair stent graft was used in the trial. This will be a huge boon to Gore, who already has FDA approval for the graft for the treatment of venous anastomotic stenosis in hemodialysis access grafts. The market potential for this indication is significant, with nearly 400,000 people undergoing dialysis each year. Adoption of stent grafts in this indication, however, would cannibalize percutaneous transluminal angioplasty (PTA) balloon catheter use in the arteriovenous access indication, which accounts for over 30% of PTA balloon catheter sales.
The trial was praised for being a randomized, prospective trial, which is expected to have a cost-effectiveness component when full data become available. It was pointed out that this kind of data will be key to supporting reimbursement for stent grafts in a dialysis indication.